ArticleFrontiers in neurology
Risk of macrovascular events among patients with ICD-defined neuromyelitis optica in Taiwan.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: An elevated risk of cardiovascular disease (CVD) and cerebrovascular disease (CBD) has been observed in patients with ICD-defined Neuromyelitis Optica (hereinafter referred to as NMO). However, population-based research on this topic remains limited. In this study, the risk of macrovascular events was compared between individuals with NMO and a matched population without NMO in Taiwan. Methods: Data for this retrospective cohort study were collected from a nationwide database in Taiwan. A total of 1,376 patients with new-onset NMO between 2003 to 2020 were enrolled. A Cox proportional hazards model was constructed to investigate CVD and CBD risk in patients with NMO and controlled for relevant variables. Results: After relevant variables were controlled for, patients with NMO exhibited a significantly higher risk of CVD (adjusted hazard ratio [aHR] = 1.40; 95% confidence interval [CI] = 1.11-1.77) and CBD (aHR = 3.37; 95% CI = 2.69-4.22) than matched controls. Significant associations were observed between NMO and ischemic stroke, hemorrhagic stroke, and transient ischemic attack but not acute myocardial infarction, atrial fibrillation, coronary artery disease, or heart failure. Conclusion: Individuals with NMO exhibited an elevated risk of CBD. Conversely, NMO was not associated with an elevated risk of certain CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.